Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04634357
Other study ID # ETUS20AFPAR123
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 19, 2022
Est. completion date January 31, 2028

Study information

Verified date March 2024
Source Eureka Therapeutics Inc.
Contact Teresa Klask, BS
Phone 510-722-8719
Email Teresa.Klask@eurekainc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.


Description:

The trial starts with a dose escalation phase. A traditional dose escalation model (3+3) design will be used to determine the recommended phase II dose (RP2D). Subjects will then be treated at the RP2D in the expansion phase of the trial. Following treatment, tumor response assessments will be performed at Months 1, 3, 6, 9, 12, 18, and 24. At each tumor response assessment visit, imaging will be performed (triphasic CT Scan) and used for response evaluation. Serum AFP levels will also be measured at each tumor response assessment visit. The active assessment phase of the study will continue for 2 years. Subjects will be followed for 15 years post-treatment for assessment of treatment safety and overall survival.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date January 31, 2028
Est. primary completion date January 31, 2026
Accepts healthy volunteers No
Gender All
Age group 1 Year to 21 Years
Eligibility Inclusion Criteria: 1. Histologically confirmed HB, HCN-NOS, or HCC with serum AFP >100ng/mL at the time of screening and following the most recent line of therapy. 2. Disease reoccurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., refractory). 3. Age = 1 year and = 21 years. 4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele. 5. Life expectancy of > 4 months per the Investigator's opinion. 6. Lansky or Karnofsky Performance Scale = 70. 7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion = 5 mm in diameter or two (2) or more lesions = 3 mm in diameter. For the dose-expansion cohort, subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 8. Child-Pugh score of A6 or better. 9. Adequate organ function. Exclusion Criteria: 1. Recurrent HB who are candidates for complete surgical resection (e.g., isolated pulmonary relapse amendable to pulmonary metastasectomy). 2. Pre-existing illness including heart failure, uncontrolled pulmonary disease not cancer-related, or psychiatric illness/social situation that would limit compliance with study requirements. 3. Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled. 4. Any known active malignancy (other than HB, HCN-NOS, or HCC). 5. Pregnant or lactating women. 6. Received the following within two (2) weeks of leukapheresis or within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, other anti-cancer therapies (including immunotherapeutic agents), immunosuppressive therapy, or systemic corticosteroids at doses greater than 5 mg/day of prednisone or equivalent doses of other corticosteroids. (Note: Topical and inhaled corticosteroids in standard doses and physiological replacement doses of corticosteroids for adrenal insufficiency are allowed). 7. Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study. 8. Contraindication for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide. 9. Active autoimmune disease requiring systemic immunosuppressive therapy. 10. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to partial or complete obstruction which, in the opinion of the Investigator, would make the subject unsuitable for the study. 11. History of organ transplant. 12. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).

Study Design


Intervention

Drug:
ET140203 T Cells
Biological/Vaccine: ET140203 autologous T-cell product Autologous T cells transduced with lentivirus encoding an ET140203 expression construct

Locations

Country Name City State
United States Dana-Farber/Boston Children's Cancer and Blood Disorders Center Boston Massachusetts
United States UCSF Benioff Children's Hospitals San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Eureka Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence rates of adverse events (AEs) after infusion of ET140203 T cells Safety of ET140203 T cells as assessed by the number of adverse events (AEs) after infusion 28 days
Primary Severity rates of adverse events (AEs) after infusion of ET140203 T cells Safety of ET140203 T cells as assessed by the severity of adverse events (AEs) after infusion. 28 days
Primary Incidence rates of dose limiting toxicities (DLTs) after infusion of ET140203 T cells Tolerability of ET140203 T cells after infusions assessed by committee review of dose limiting toxicities (DLTs) 28 days
Primary The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT The RP2D will be determined by the study Dose Escalation Committee (DEC) and primarily based on DLTs. Up to 2 years
Secondary Assess the efficacy of ET140203 T cells in pediatric subjects with relapsed/refractory HB, HCN-NOS, or HCC Response rate will be assessed by radiographic scans and assessed according to RECIST criteria. Up to 2 years
Secondary Determine the pharmacokinetics of ET140203 T cells after infusion. Assess the expansion and persistence of ET140203 T cells circulating in blood over time. Up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT05160740 - Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer N/A
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Enrolling by invitation NCT04466124 - Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT03059238 - Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure Phase 3
Recruiting NCT02632188 - Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT01388101 - Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor) N/A
Completed NCT00980239 - HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Phase 1
Completed NCT01042041 - Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer Phase 1
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Completed NCT00543777 - Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Phase 1/Phase 2